Targeting the TME and the Development of Effective Therapeutics Against Solid Tumors
Targeting TME as a potent therapeutic strategy has long held promise in cancer research. The success of immune therapy in hematological malignancies and various therapeutic modalities targeting the cellular, the ECM, and the underlying signaling pathways presents a promising avenue for the next generation of cancer treatments. Further work is needed to assemble a much more accurate systemic picture of the TME and realize their therapeutic potential. ACROBiosystems is committed to providing high-quality soluble and membrane protein targets and custom services to support the next generation of antibody and cellular therapies against solid tumors.